is tirzepatide considered a peptide Peptide? The Classification Question Explained Best Peptides for Weight Loss:

This is about saving hearts Who qualifies: Adults with established CVD + overweight/obesity (BMI 27 kg/m) The drug: Semaglutide 2.4mg once-weekly subcutaneous injection (GLP-1 RA) Titrated to maintenance dose Adjunct to lifestyle counselling & standard care Why NICE said yes: Reduces risk of MACE (heart attack, stroke, CV death) in this population Cost-effective within NHS thresholds (20,00030,000/QALY) Commercial agreement already in place with NHS The pathway is simple: Assess CVD risk Lifestyle counselling Add semaglutide Monitor This follows SELECT trial data showing ~20% MACE reduction independent of weight loss We are watching GLP-1s redefine cardiovascular medicine in real time From diabetes obesity now primary CV risk reduction Whats next

M.WeighillD.SonawaneA

Join the numerous Cockeysville residents who have benefited from Klinics comprehensive weight management solutions, combining medical expertise with the convenience of telehealth

The GLP-1 RA improves outcomes for obese patients with hidradenitis suppurativa, according to new research presented at the EADV Congress 2024

Conclusions Semaglutide 2.4 mg is likely to be a short-term, cost-effective treatment option for adults who are overweight or have obesity without diabetes in Greece

Each teaspoon (5ml) contains: Setria L-Glutathione reduced 450mg